vertical axis actigraph cut points  (ActiGraph llc)

Journal: Alzheimer's & Dementia

Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

doi: 10.1002/alz.71147

Figure Lengend Snippet: Lumipulse plasma p‐tau217 measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau

Article Snippet: Sensitivity analyses were undertaken using four further definitions of AD status: The “amyloid and p‐tau” definition was CSF Aβ 42 /Aβ 40 ratio ≤ 0.065 and p‐tau181 ≥ 57pg/mL; The “clinical AD status” definition was based on the most recent clinical diagnosis confirmed via clinical follow‐up and informed by results of CSF testing using whichever AD biomarker assay combination was in clinical use at the time of testing, as between August 2017 and March 2020 the Innotest (Fujirebio) enzyme‐linked immunosorbent assay for Aβ 42 and total tau were used, and between April 2020 and September 2024 the aforementioned Lumipulse CSF assays for Aβ 42 /Aβ 40 and p‐tau181 were used; The “Malmö cohort” definition was based on a cut‐point of Lumipulse CSF Aβ 42 /p‐tau181 < 11.94 recently published by Palmqvist et al. in a paper assessing the translation of Lumipulse plasma p‐tau217 cut‐points across multiple European memory clinic cohorts; The “FDA” definition was based on a cut‐point of Lumipulse CSF Aβ 42 /Aβ 40 < 0.073 being considered by the United States Food and Drug Administration as consistent with a positive amyloid PET scan.

Techniques: Clinical Proteomics, Derivative Assay

Journal: Alzheimer's & Dementia

Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

doi: 10.1002/alz.71147

Figure Lengend Snippet: Relative change in concentration of plasma p‐tau217 across pre‐analytical sample handling conditions: (A) pre‐centrifugation delay at RT, (B) pre‐centrifugation delay at 2 to 8°C, (C) post‐centrifugation delay, (D) number of freeze–thaw cycles, compared to the baseline condition using the ALZpath and Lumipulse assays ( n = 10 per experiment, data presented as median ± IQR, dotted lines represent the lower and upper bounds of a 10% difference threshold from the baseline condition). IQR, interquartile range; p‐tau, phosphorylated tau; RT, room temperature

Article Snippet: Sensitivity analyses were undertaken using four further definitions of AD status: The “amyloid and p‐tau” definition was CSF Aβ 42 /Aβ 40 ratio ≤ 0.065 and p‐tau181 ≥ 57pg/mL; The “clinical AD status” definition was based on the most recent clinical diagnosis confirmed via clinical follow‐up and informed by results of CSF testing using whichever AD biomarker assay combination was in clinical use at the time of testing, as between August 2017 and March 2020 the Innotest (Fujirebio) enzyme‐linked immunosorbent assay for Aβ 42 and total tau were used, and between April 2020 and September 2024 the aforementioned Lumipulse CSF assays for Aβ 42 /Aβ 40 and p‐tau181 were used; The “Malmö cohort” definition was based on a cut‐point of Lumipulse CSF Aβ 42 /p‐tau181 < 11.94 recently published by Palmqvist et al. in a paper assessing the translation of Lumipulse plasma p‐tau217 cut‐points across multiple European memory clinic cohorts; The “FDA” definition was based on a cut‐point of Lumipulse CSF Aβ 42 /Aβ 40 < 0.073 being considered by the United States Food and Drug Administration as consistent with a positive amyloid PET scan.

Techniques: Concentration Assay, Clinical Proteomics, Analytical Sample Preparation, Centrifugation

Journal: Alzheimer's & Dementia

Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

doi: 10.1002/alz.71147

Figure Lengend Snippet: Lumipulse plasma p‐tau217 measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau

Article Snippet: Palmqvist et al. derived Lumipulse plasma p‐tau217 cut‐points of 0.22 and 0.34 pg/mL for 95% sensitivity and 95% specificity for detecting Lumipulse CSF Aβ42/p‐tau181 ratio < 11.94 (where the lower cut‐point in our CSF cohort was 0.239 pg/mL compared to AD status defined by CSF Aβ42/Aβ40 ratio and p‐tau181).

Techniques: Clinical Proteomics, Derivative Assay

Journal: Alzheimer's & Dementia

Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

doi: 10.1002/alz.71147

Figure Lengend Snippet: Relative change in concentration of plasma p‐tau217 across pre‐analytical sample handling conditions: (A) pre‐centrifugation delay at RT, (B) pre‐centrifugation delay at 2 to 8°C, (C) post‐centrifugation delay, (D) number of freeze–thaw cycles, compared to the baseline condition using the ALZpath and Lumipulse assays ( n = 10 per experiment, data presented as median ± IQR, dotted lines represent the lower and upper bounds of a 10% difference threshold from the baseline condition). IQR, interquartile range; p‐tau, phosphorylated tau; RT, room temperature

Article Snippet: Palmqvist et al. derived Lumipulse plasma p‐tau217 cut‐points of 0.22 and 0.34 pg/mL for 95% sensitivity and 95% specificity for detecting Lumipulse CSF Aβ42/p‐tau181 ratio < 11.94 (where the lower cut‐point in our CSF cohort was 0.239 pg/mL compared to AD status defined by CSF Aβ42/Aβ40 ratio and p‐tau181).

Techniques: Concentration Assay, Clinical Proteomics, Analytical Sample Preparation, Centrifugation

Journal: BMC Ophthalmology

Article Title: Evaluation of serum YKL-40 and Galectin-3 as predictive biomarkers for proliferative vitreoretinopathy in rhegmatogenous retinal detachment: a prospective comparative study

doi: 10.1186/s12886-025-04553-3

Figure Lengend Snippet: Receiver operating characteristic (ROC) curves of serum YKL-40 and Galectin-3 for predicting proliferative vitreoretinopathy (PVR) development in rhegmatogenous retinal detachment (RRD) (a) ROC curve of serum YKL-40 demonstrating good discriminative performance for predicting PVR (AUC = 0.739, 95% CI = 0.621–0.856, p = 0.001; optimal cut-off = 26.9 ng/mL, sensitivity = 68.8%, specificity = 67.6%) (b) ROC curve of serum Galectin-3 showing moderate predictive accuracy (AUC = 0.643, 95% CI = 0.510–0.777, p = 0.045; optimal cut-off = 99.7 pg/mL, sensitivity = 62.5%, specificity = 58.8%) The diagonal line represents the reference line for random classification (AUC = 0.5)

Article Snippet: Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis, and the optimal cut-off points for YKL-40 and Galectin-3 were determined using the Youden index.

Techniques: